Comparison of the safety and efficacy of emboli prevention devices versus platelet glycoprotein IIb/IIIa inhibition during carotid stenting
- 1 March 2005
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 95 (6) , 791-795
- https://doi.org/10.1016/j.amjcard.2004.11.041
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Protected Carotid-Artery Stenting versus Endarterectomy in High-Risk PatientsNew England Journal of Medicine, 2004
- Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trialThe Lancet, 2000
- Recognition of the Importance of Embolization in Atherosclerotic Vascular DiseaseCirculation, 2000
- Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa ReceptorsNew England Journal of Medicine, 1999
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- Elective Stenting of the Extracranial Carotid ArteriesCirculation, 1997
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 1994
- Beneficial Effect of Carotid Endarterectomy in Symptomatic Patients with High-Grade Carotid StenosisNew England Journal of Medicine, 1991
- Measurements of acute cerebral infarction: a clinical examination scale.Stroke, 1989
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJournal of the American College of Cardiology, 1988